Association of sex and age on outcomes of maintenance treatment in patients with advanced esophagogastric adenocarcinoma: an exploratory analysis of the randomized AIO-YMO-0111-MATEO trial

PURPOSE: Sex and age have an impact on efficacy and toxicity of chemotherapy (ctx) in patients (pts) with esophagogastric adenocarcinoma (EGA). However, data are limited, as clinical trials frequently do not report sex-specific differences and older pts are often underrepresented. METHODS: MATEO is an international randomized trial, confirming non-inferiority of S-1 maintenance therapy compared to continued platinum-based ctx in pts with advanced EGA without disease progression after 3 months of ctx. Toxicity pattern favored S-1 monotherapy. We conducted a post hoc exploratory analysis to assess the impact of sex and age on treatment outcomes. RESULTS: In the per-protocol population, 112 pts (72.7%) were male and 42 (27.3%) were female. 37.7% of pts were ≥ ​70 years. Female pts more often had distal stomach tumors (64.3%), while male pts had more esophagogastric junction tumors (76.7%). In a pooled analysis, female pts showed significantly longer progression-free survival (PFS) (median 9.9 vs. 4.3 months, HR 0.56 [95% CI 0.38-0.83], log-rank: p = 0.0033), and overall survival (OS) (median 14.4 vs. 12.2 months, HR 0.65 [95% CI 0.44-0.97], log-rank: p = 0.0348). No age-related differences in PFS and OS were observed between pts ≥ 70 years and < 70 years. In multivariate analyses, female sex, but not younger age, was associated with a trend towards improved OS. No significant sex- or age-specific differences in terms of toxicity were observed. CONCLUSION: Primary tumor location differed by sex. A trend for superior outcome in female pts was observed, whereas age did not have a significant impact on outcome.

Authors

Institutions

Publication Details

Journal
Journal of Cancer Research and Clinical Oncology
Published
2026-11-13
DOI
https://doi.org/10.1007/s00432-026-06662-y
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of sex and age on outcomes of maintenance treatment in patients with advanced esophagogastric adenocarcinoma: an exploratory analysis of the randomized AIO-YMO-0111-MATEO trial

Benoist Chibaudel, S. Lorenzen, Gertraud Stocker, Florian Lordick et al.
Journal of Cancer Research and Clinical Oncology
Gastric Cancer Management and Outcomes
article

Association of sex and age on outcomes of maintenance treatment in patients with advanced esophagogastric adenocarcinoma: an exploratory analysis of the randomized AIO-YMO-0111-MATEO trial

Benoist Chibaudel, S. Lorenzen, Gertraud Stocker, Florian Lordick, Maren Knödler, R. Greil, J. Larcher-Steiner, M. Perwög, T. Ettrich, S. Held, R. Stelmach, G. M. Haag, F. Longo
article en

Abstract

PURPOSE: Sex and age have an impact on efficacy and toxicity of chemotherapy (ctx) in patients (pts) with esophagogastric adenocarcinoma (EGA). However, data are limited, as clinical trials frequently do not report sex-specific differences and older pts are often underrepresented. METHODS: MATEO is an international randomized trial, confirming non-inferiority of S-1 maintenance therapy compared to continued platinum-based ctx in pts with advanced EGA without disease progression after 3 months of ctx. Toxicity pattern favored S-1 monotherapy. We conducted a post hoc exploratory analysis to assess the impact of sex and age on treatment outcomes. RESULTS: In the per-protocol population, 112 pts (72.7%) were male and 42 (27.3%) were female. 37.7% of pts were ≥ ​70 years. Female pts more often had distal stomach tumors (64.3%), while male pts had more esophagogastric junction tumors (76.7%). In a pooled analysis, female pts showed significantly longer progression-free survival (PFS) (median 9.9 vs. 4.3 months, HR 0.56 [95% CI 0.38-0.83], log-rank: p = 0.0033), and overall survival (OS) (median 14.4 vs. 12.2 months, HR 0.65 [95% CI 0.44-0.97], log-rank: p = 0.0348). No age-related differences in PFS and OS were observed between pts ≥ 70 years and < 70 years. In multivariate analyses, female sex, but not younger age, was associated with a trend towards improved OS. No significant sex- or age-specific differences in terms of toxicity were observed. CONCLUSION: Primary tumor location differed by sex. A trend for superior outcome in female pts was observed, whereas age did not have a significant impact on outcome.

Journal of Cancer Research and Clinical OncologyVol. 152(11)
German Cancer Research Center (DE), Heidelberg University (DE), Paracelsus Medical University (AT), University Hospital Heidelberg (DE), Humboldt-Universität zu Berlin (DE), National Center for Tumor Diseases (DE), University Hospital Leipzig (DE), AIO Studien gGmbH (DE), Institut Hospitalier Franco Britannique (FR), University Hospital Ulm (DE), Hospital Universitario Ramón y Cajal (ES), Fondation Cognacq-Jay (FR), Technical University of Munich (DE), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE), Leipzig University (DE)
Amgen, Eli Lilly and Company, AstraZeneca, Gilead Sciences, Taiho Pharmaceutical, BeiGene, Eisai, Astellas Pharma, Servier, Ipsen, Nordic Pharma Group, Julius Clinical, Daiichi Sankyo Europe
Good health and well-being
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon